Metcalf Patricia A, Wells Susan, Scragg Robert K R, Jackson Rod
Division of Epidemiology and Biostatistics, School of Population Health, Tamaki Campus, University of Auckland, Private Bag 92019, Auckland, New Zealand.
N Z Med J. 2008 Sep 5;121(1281):49-57.
To compare three methods of assessing 5-year absolute risk of cardiovascular disease (CVD) in adults with type 2 diabetes; the Framingham CVD equation, the UK Prospective Diabetes Study (UKPDS) coronary heart disease plus stroke equations and the New Zealand Guidelines Group (NZGG)-modified Framingham CVD equation.
Participants were 423 people with newly (n=118) or previously diagnosed (n=305) Type 2 diabetes mellitus aged 35 to 74 years with no past history of cardiovascular disease or nephropathy from an interviewed study population of 4049 adults. Absolute 5-year CVD risks were calculated in 5-year age bands by gender; Maori, Pacific, and European ethnicity; and newly and previously diagnosed diabetes.
The mean 5-year CVD risk score was 2.9% (95%CI: 2.40-3.42; p<0.0001) lower for the UKPDS risk engine compared to the original Framingham equation in absolute terms, and 7.6% (95%CI: 7.05-8.08; p<0.0001) lower than the NZGG-modified Framingham equation. In general, 5-year CVD risks were highest using the NZGG-modified equation, intermediate using the original Framingham equation and lowest using the combined UKPDS coronary heart disease plus stroke equations, in all age groups by gender, ethnicity, and time of diagnosis of Type 2 diabetes. However, the 5-year CVD risks are themselves potentially low as they include treated blood pressure and lipid values. Compared to the UKPDS 15% level of risk, the NZ Guidelines modified 15% level of risk results in people with diabetes being recommended for CVD drug management 10 to 17 years earlier.
In general, among people with Type 2 diabetes, the Framingham equations showed higher 5-year CVD risk estimates compared to combined UKPDS coronary heart disease plus stroke equations and the NZGG-modified Framingham equation showed the highest 5-year CVD risks. In practice, people with type 2 diabetes will be managed earlier and more intensively based on their risk estimated by the current NZGG guidelines than if the UKPDS or original Framingham equations were used.
比较三种评估2型糖尿病成年患者心血管疾病(CVD)5年绝对风险的方法;弗雷明汉心血管疾病方程、英国前瞻性糖尿病研究(UKPDS)冠心病加中风方程以及新西兰指南小组(NZGG)修正的弗雷明汉心血管疾病方程。
研究对象为423名年龄在35至74岁之间、无心血管疾病或肾病既往史的新诊断(n = 118)或既往诊断(n = 305)的2型糖尿病患者,来自4049名成年受访者的研究人群。按性别、毛利族、太平洋族和欧洲族裔以及新诊断和既往诊断的糖尿病情况,以5岁年龄组计算5年CVD绝对风险。
就绝对值而言,与原始弗雷明汉方程相比,UKPDS风险评估工具得出的5年CVD风险评分平均低2.9%(95%CI:2.40 - 3.42;p < 0.0001),比NZGG修正的弗雷明汉方程低7.6%(95%CI:7.05 - 8.08;p < 0.0001)。总体而言,在所有按性别、族裔和2型糖尿病诊断时间划分的年龄组中,使用NZGG修正方程得出的5年CVD风险最高,使用原始弗雷明汉方程居中,使用UKPDS冠心病加中风方程组合得出的风险最低。然而,由于5年CVD风险包含已治疗的血压和血脂值,其本身可能较低。与UKPDS的15%风险水平相比,NZ指南修正的15%风险水平会使糖尿病患者早10至17年被推荐进行CVD药物管理。
总体而言,在2型糖尿病患者中,与UKPDS冠心病加中风方程组合相比,弗雷明汉方程显示出更高的5年CVD风险估计值,而NZGG修正的弗雷明汉方程显示出最高的5年CVD风险。在实际应用中,与使用UKPDS或原始弗雷明汉方程相比,根据当前NZGG指南估计的风险,2型糖尿病患者将更早且更强化地接受管理。